Supplementary Figure 4: Identification of MAYA-associated proteins, characterization of MAYA transcript and its correlation with lung cancer.
From: A ROR1–HER3–lncRNA signalling axis modulates the Hippo–YAP pathway to regulate bone metastasis
(a) Summary of the top MAYA-associated proteins identified by RNA pull-down followed by MS in MDA-MB-231 cells. (b) Determination of MAYA transcript in MDA-MB-231 cells by 5′-and 3′-RACE. R1: repeat 1, R2: repeat 2. (c) Top, northern blot detection of MAYA in pre-made human tissue RNA blots; bottom, RNA gel electrophoresis. (d) Top, northern blot detection of MAYA in MDA-MB-231 cells with indicated treatment; bottom, RNA gel electrophoresis. (e) Examination of MAYA expression in multiple tumor types and their normal counterparts by RNAscope assay. (f) MAYA RNAscope staining intensities in normal lung tissues, lung adenocarcinomas, non-metastatic (TnN0M0) and metastatic (TnN > 0M ≥ 0) lung adenocarcinomas (n = 75, 75, 50 and 25 lung tissues/adenocarcinomas respectively, median, one-way ANOVA) (g) Kaplan-Meier survival analysis of MAYA low and high lung cancer patients (n = 21 and 54 patients respectively, log rank test). (h and i) RT-qPCR detection of MAYA and CTGF expression level in MCF-7 cells transfected with the indicated siRNAs that grown under spare or confluent culture conditions (h) or followed by lysophosphatidic acid (LPA) treatment (1 μM, 2 h) (i). For h and i, mean ± s.e.m. were derived from n = 3 independent experiments (n.s., P > 0.05 and∗∗P < 0.01, two-tailed paired Student’s t-test). Unprocessed original scans of all blots/gels with size marker are shown in Supplementary Fig. 9.
